Case study · 001
Cullinan Pearl
A preclinical EGFR ex20ins program, taken through proof of concept and home.
The thesis was a single, badly served patient population — and a small molecule with a real mechanistic answer. The exit was the natural endpoint, not the strategy.
In 2017, Cullinan Pearl was a preclinical asset with a clean ex20ins selectivity profile and no comparable competitor in clinic. We co-led the Series A alongside MPM Capital and F-Prime, and stayed in through proof of concept.
By Phase II the molecule had registrational potential in a population of roughly 2% of NSCLC patients — small in label, large in unmet need. Taiho parent acquired the program in 2023 to take it through global registration. Asia commercialization was the strategic bridge; the financial return was the consequence, not the asterisk.
